Navigation Links
Baxter Initiates Phase III Trial for the Treatment of Alzheimer's Disease
Date:9/22/2008

DEERFIELD, Ill., Sept. 22 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced initiation of a Phase III clinical trial following U.S. Food and Drug Administration (FDA) review of its investigational new drug application to evaluate GAMMAGARD LIQUID [Immune Globulin Intravenous (IGIV)], marketed as KIOVIG in European Union, for the treatment of mild-to-moderate Alzheimer's disease. This trial is expected to be the first of two pivotal Phase III trials required to support filing for regulatory approval for GAMMAGARD LIQUID as a potential treatment for the disease.

The Phase III trial is a prospective, 18-month, randomized, double-blind, placebo-controlled, two dose-arm, parallel study in 360 subjects of both genders, ages 50 to 89 years old, with dementia of mild-to-moderate severity. The study will determine whether GAMMAGARD LIQUID treatment results in a significantly slower rate of decline of cognitive and other functions compared to placebo. Approximately 40 U.S. leading academic centers have been identified and will begin clinical trial enrollment within the next several weeks.

Efficacy will be assessed by two primary endpoints:

-- Cognitive outcomes using the Alzheimer's Disease Assessment Scale- Cognitive Subscale score (ADAS-Cog), and

-- Global clinical outcome as assessed by the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change rating (ADCS-CGIC).

Secondary endpoints to be assessed at 18 months include behavioral, functional and quality of life outcome measures. Other secondary endpoints will include several plasma, cerebrospinal fluid, and imaging biomarkers to assess disease progression and response to therapy.

The trial is sponsored by Baxter and partially funded by the National Institutes of Health (NIH) through the Alzheimer's Disease Cooperative Study (ADCS). The ADCS is a cooperative agreement between the National Institute of Aging and the University of Calif
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
2. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
3. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
4. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
5. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
6. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
7. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
8. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
9. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
10. Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections
11. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
(Date:9/17/2014)... 2014 Women everywhere know how frustrating a ... uncomfortable, they,re often also embarrassing and have a way ... Support ( http://ph-defense.com ) is a new, over-the-counter product ... homeopathic product. Odor, discharge, and discomfort ... infection. In many cases, the cause of such problems ...
Breaking Medicine Technology:Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2
... 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... to reprise key carfilzomib data presentations that were featured at ... San Diego, California. The teleconference will begin at ... Interested parties may access the teleconference and the presentation that ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, responded today to the allegations raised ... dated December 6, 2011. The Company maintains that the ... "Report") concern matters which have long been disclosed in ...
Cached Medicine Technology:China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 2China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 3China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 4China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 5China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 6
(Date:9/18/2014)... (PRWEB) September 18, 2014 According to the ... from eczema, with many of them being children. In fact, ... diagnosed as babies and children. The millions of children who ... be brought on by eczema. A new book has been ... they are and to find relief from the condition over ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 SpineFrontier ... team and surgeon partners in Less Exposure Surgery ... SpineFrontier, Tamara authored an extensive education curriculum and ... Masters in Science in Organizational Leadership, and has ... for eleven years. Bringing her to the team ...
(Date:9/18/2014)... 18, 2014 First Choice Emergency ... rooms in the United States, named Douglas J. Harrison, ... City-Lakes facility. , “We are pleased to welcome ... director of our new Missouri City-Lakes facility,” said Dr. ... Emergency Room. , Dr. Harrison received his undergraduate ...
(Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major developmental milestone ... mere 8 months after company startup. Its novel product ... enzyme used in the “Biologics” industry for discovery and ... pathology on Mass Spec devices. PRIME™ is being sold ... market (PNGase F PRIMETM). N-Zyme is currently evaluating ...
(Date:9/17/2014)... September 18, 2014 Recently, BambooIndustry.com, an outstanding ... of bamboo floorings . There are more than 1000 ... has launched a big promotion for these useful items. Each ... 30 % off. , “We are very proud to ... to say, all these items are made with natural materials ...
Breaking Medicine News(10 mins):Health News:New Book Helps Millions of Children Deal With The Emotional Pains of Suffering From Eczema 2Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:More Than 1000 Items Added To BambooIndustry.com’s Bamboo Flooring Collection 2
... a newly developed drug, which is aimed at a particular ... tumour growth, is active in patients with advanced cancers and, ... The drug, ACE-041, targets a different molecular pathway to ... treat cancer. Results from a phase I clinical ...
... surgery should receive a risk assessment before their procedure ... in the legs or lungs, according to research at ... that 1 in 9 patients at highest risk based ... clot-preventing medications after surgery. Published in the November ...
... into mice with metastatic melanoma has resulted in permanent ... cancer, according to an article to be published in ... Clinical Investigation . The online version is now available. ... modified lentivirus to introduce a potent anti-melanoma T cell ...
... federal agencies recently cosponsored a set of expert work ... to psychological adjustment and traumatic brain injury (TBI). ... behavioral neuroscience at Boston University School of Medicine, chaired ... Dr. Kaloupek,s work at the National Center for PTSD ...
... of six national participants in a pilot study that ... families have a smoother care experience and better outcomes ... to reliably adhere to best practice standards. The ... the Society of Thoracic Surgeons (STS) will study clinician ...
... have been stymied for years over the fact that people ... response to the pathogen antibodies that turn out to ... Medical Center can explain why: Some of the earliest and ... the virus until after it,s already invaded a healthy cell. ...
Cached Medicine News:Health News:Researchers find new target for stopping tumors developing their own blood supply 2Health News:Researchers find new target for stopping tumors developing their own blood supply 3Health News:Assessment tool predicts blood clot risk after plastic surgery 2Health News:Assessment tool predicts blood clot risk after plastic surgery 3Health News:Gene therapy for metastatic melanoma in mice produces complete remission 2Health News:Researchers identify PTSD measures for use in traumatic brain injury research 2Health News:Lung cancer patients are the centerpiece for Northwestern medicine quality of care study 2Health News:Why so many antibodies fail to protect against HIV infection 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: